Real-World Clinical and Patient-Reported Outcomes from the Longitudinal Telotristat Ethyl Treatment Registry of Patients with Neuroendocrine Tumors

BACKGROUND: Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor approved for the treatment of carcinoid syndrome diarrhea (CSD) in combination with somatostatin analogs (SSAs). METHODS: This prospective, observational, single-arm study evaluated long-term patient-reported outcomes for...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Daneng, Darden, Christina, Osman, Noran, Sayeed, Salma, Jackson, Laurin, Garbinsky, Diana, Chauhan, Aman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575469/
https://www.ncbi.nlm.nih.gov/pubmed/36262750
http://dx.doi.org/10.2147/CMAR.S386419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575469/
https://www.ncbi.nlm.nih.gov/pubmed/36262750
http://dx.doi.org/10.2147/CMAR.S386419

Ejemplares similares